Blackstone Explores Sale of Anthos Therapeutics

Private equity firm Blackstone (BX.N) is exploring the sale of Anthos Therapeutics, a developer of a new generation of blood thinners it launched four years ago with backing from Novartis (NOVN.S), according to people familiar with the matter. Anthos, which does not yet have any approved products or generate revenue, could be worth several billion dollars in a potential sale, significantly more than the $250 million Blackstone invested when it founded Anthos in 2019, the sources said.

Read the full article: Blackstone Explores Sale of Anthos Therapeutics //

Source: https://www.reuters.com/markets/deals/blackstone-explores-sale-anthos-therapeutics-sources-2023-12-04

Leave a Comment

Your email address will not be published.

Scroll to Top